Buenos Aires - Delayed Quote ARS

Johnson & Johnson (JNJ.BA)

11,300.00

0.00

(0.00%)

At close: January 10 at 4:58:43 PM GMT-3

Cramer on Johnson & Johnson (JNJ): A Value Trap Amid Lawsuits and Setbacks

We recently published a list of Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks ahead of major AI event that Jim Cramer discussed. In his appearance on Squawk on the Street the […]

Insider Monkey yesterday

JNJ
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.

Motley Fool yesterday

MSFT

JNJ

V
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

Zacks yesterday

JNJ

CSTL
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid

Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry.

Motley Fool 2 days ago

KO

JNJ

^DJI
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial

The trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.

Clinical Trials Arena 2 days ago

JNJ
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks 2 days ago

JNJ

THC
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

Zacks 2 days ago

JNJ

MDT

BSX
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the safety

PR Newswire 2 days ago

JNJ
Johnson & Johnson MedTech pauses Varipulse rollout in US

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Medical Device Network 2 days ago

JNJ
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product

Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.

Investor's Business Daily 3 days ago

JNJ

BSX

MDT
Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events

Johnson & Johnson (JNJ) Wednesday said it paused the rollout of Varipulse cardiac device in the US e

PREMIUM
MT Newswires 3 days ago

JNJ
J&J pauses Varipulse PFA cases in US

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for the pulsed field ablation system.

MedTech Dive 3 days ago

JNJ
The Zacks Analyst Blog Highlights NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries

NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries are part of the Zacks top Analyst Blog.

Zacks 3 days ago

JNJ

META

NVDA
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease (AD) in the Phase 2b "AuTonomy" study. The internally discovered mAb has shown the potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid (CSF) from treated AD patients, and in blocking the development

PR Newswire 3 days ago

JNJ
Johnson & Johnson (JNJ): A Bull Case Theory

We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile Investor. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson (NYSE:JNJ)’s share was trading at $146.23 as of Jan 7th. JNJ’s trailing and forward P/E were 24.17 and 13.76 respectively according to Yahoo […]

Insider Monkey 3 days ago

JNJ
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

The Phase III MARIPOSA trial involved 1,074 subjects.

Clinical Trials Arena 4 days ago

JNJ
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors

Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.

Zacks 4 days ago

JNJ
Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and Johnson & Johnson (JNJ), as well as two micro-cap stocks Rave Restaurant Group, Inc. (RAVE) and EVI Industries, Inc. (EVI).

Zacks 4 days ago

META

JNJ

NVDA
J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care

(Bloomberg) -- Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.Most Read from BloombergNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeDutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Can American Drivers Learn to Love Roundabouts?Don’t Shrink the BusCan States Hit the Brakes on Runaway Roadb

Bloomberg 4 days ago

JNJ
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regi

PR Newswire 4 days ago

JNJ

Performance Overview

Return	JNJ.BA	S&P 500
YTD	-0.22%	-1.35%
1-Year	-12.31%	+22.51%
3-Year	+54.08%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Johnson & Johnson (JNJ.BA)

Cramer on Johnson & Johnson (JNJ): A Value Trap Amid Lawsuits and Setbacks

4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid

Contineum concludes enrolment in Phase II multiple sclerosis therapy trial

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

J&J Pauses Sales of Atrial Fibrillation Device, Stock Down

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Johnson & Johnson MedTech pauses Varipulse rollout in US

J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product

Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events

J&J pauses Varipulse PFA cases in US

The Zacks Analyst Blog Highlights NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

Johnson & Johnson (JNJ): A Bull Case Theory

J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors

Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson

J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

Performance Overview